Circulating Epigenetic and Epitranscriptomic Biomarkers Identify EGFR Status and Predict TKI Response in NSCLC
核心洞察
A novel liquid biopsy approach using circulating epigenetic and epitranscriptomic biomarkers can non-invasively identify EGFR (搜索) mutation status in non-small cell lung cancer (搜索) patients.
The biomarker panel demonstrates potential to predict tyrosine kinase inhibitor (TKI) treatment response, offering a tool for personalized therapy selection.
Molecular residual disease (MRD) detection via these circulating biomarkers may enable earlier identification of relapse in early-stage resected EGFR (搜索)-mutated NSCLC.
A pair of studies published in Nature journals highlight significant advances in the use of circulating biomarkers for managing EGFR (搜索)-mutated non-small cell lung cancer (搜索) (NSCLC). The research demonstrates that epigenetic and epitranscriptomic signatures detectable in blood can identify EGFR mutation status and predict response to tyrosine kinase inhibitor (TKI) therapy, while molecular residual disease (MRD) detection offers clinical utility in monitoring early-stage resected disease.
Non-Invasive EGFR (搜索) Status Identification
One study, published in Scientific Reports, describes a liquid biopsy platform that leverages circulating epigenetic and epitranscriptomic biomarkers to determine EGFR (搜索) mutation status. This approach moves beyond traditional tissue-based genotyping, which can be limited by tumor accessibility, sample adequacy, and procedural risk. By analyzing cell-free nucleic acid modifications in peripheral blood, the method provides a minimally invasive window into the tumor's molecular profile.
The biomarker panel was developed to not only identify EGFR (搜索) mutations but also to predict how patients will respond to TKI therapy. This dual capability—diagnostic and predictive—positions the assay as a potentially valuable tool for guiding first-line treatment decisions in NSCLC, where EGFR-targeted agents represent a cornerstone of precision oncology.
Molecular Residual Disease Detection in Early-Stage Disease
A complementary study in Nature Communications examines the clinical utility of MRD detection in patients with early-stage, resected EGFR (搜索)-mutated NSCLC. Following surgical resection, the presence of molecular residual disease—detectable through circulating tumor-derived signals—can indicate incomplete eradication of disease and heightened risk of recurrence.
The research underscores the potential for serial MRD monitoring to identify patients who may benefit from adjuvant therapy intensification or, conversely, those who might safely avoid unnecessary treatment. In the adjuvant setting, where overtreatment remains a significant concern, such biomarker-driven stratification could refine risk assessment beyond conventional pathological staging.
Clinical Implications
Together, these findings advance the concept of comprehensive liquid biopsy-based management in EGFR (搜索)-mutated NSCLC. From initial diagnosis and treatment selection through post-surgical surveillance, circulating biomarkers offer a continuum of actionable information. The non-invasive nature of these assays facilitates repeated sampling, enabling dynamic monitoring of disease evolution and therapeutic response over time.
The integration of epigenetic and epitranscriptomic features represents a novel dimension in liquid biopsy development, complementing existing approaches that focus primarily on genetic alterations such as circulating tumor DNA mutations. As these technologies progress toward clinical validation, they hold promise for improving outcomes through more precise, personalized, and timely clinical decision-making in lung cancer care.